The bleeding costs of intensive vs. less intensive antithrombotic strategies: a meta-regression analysis
With currently used antithrombotic regimens, ASCVD event reduction by more intensive treatment no longer increases risk of intracranial bleeding. Fatal hemorrhage remains a seemingly inevitable cost of ASCVD reduction by antithrombotic treatment intensification, albeit at low absolute risks.
Authors
- Kirsten A. Ziesemer (ORCID: https://orcid.org/0000-0001-7783-1126)
- Jonne J. Sikkens (ORCID: https://orcid.org/0000-0001-5481-5596)
- Sten E Deurvorst
- Yvo M. Smulders (ORCID: https://orcid.org/0000-0002-6680-8649)
- Esther M E El-Hage
- Nienke van Wingerden
Institutions
- Acıbadem University (TR)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
- Rotterdam University of Applied Sciences (NL)
Publication Details
- Journal
- European Heart Journal - Quality of Care and Clinical Outcomes
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1093/ehjqcco/qcaf128
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00